Bristol-Myers Squibb and Syngene International Extend Research Collaboration

  Bristol-Myers Squibb and Syngene International Extend Research Collaboration

Business Wire

PRINCETON, N.J. & BANGALORE, India -- June 3, 2014

Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India’s largest
contract research organization, today announced a five-year extension of their
drug discovery and development collaboration in India. Financial terms were
not disclosed.

Since 2007, Bristol-Myers Squibb has been working with Syngene and its
corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal
and process chemistry, biology, biotechnology, biomarkers, drug metabolism and
pharmacokinetics, analytical research, and pharmaceutical development at the
Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.

The U.S.-India collaboration has produced six drug candidates for further
study and also helped Bristol-Myers Squibb reduce the time and costs
associated with advancing new compounds to first-in-human studies. One drug
candidate currently in clinical trials was discovered at BBRC and early
nonclinical development work done at BBRC has enabled most of Bristol-Myers
Squibb’s small molecule assets to advance to later stages of development over
the last five years.

Commenting on the new agreement, Peter Bains, director, Syngene International,
said: “We are extremely delighted to extend our discovery and development
partnership with Bristol-Myers Squibb for another five years. This extension
reflects the strength of our existing collaboration which has delivered many
successful outcomes. The scope of Syngene’s engagement has expanded to
encompass a broad range of integrated service offerings across the drug
discovery and development continuum. We remain committed to supporting
Bristol-Myers Squibb in their pursuit of developing new and innovative
medicines for the future.”

Francis Cuss, executive vice president and chief scientific officer,
Bristol-Myers Squibb, said: “I am excited about the opportunity to continue
our highly productive collaboration with Biocon and Syngene. The BBRC has
supported the nonclinical development of a large proportion of our
small-molecule portfolio assets since its inception, and is a premier example
of the high-quality innovative drug hunting that is taking place in India
today.”

Bristol-Myers Squibb and Syngene jointly developed the BBRC at Biocon Park in
Bangalore. Over the years, BBRC has become Bristol-Myers Squibb’s largest
research and development center outside the United States, housing more than
400 scientists.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit www.bms.com or
follow us on Twitter at http://twitter.com/bmsnews/.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995 regarding the
research, development and commercialization of pharmaceutical products. Such
forward-looking statements are based on current expectations and involve
inherent risks and uncertainties, including factors that could delay, divert
or change any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement can be
guaranteed. Among other risks, there can be no guarantee that the compounds
mentioned in this release will move into full product development, that the
clinical trials of these compounds will support regulatory filings, that these
compounds will receive regulatory approval or, if approved, that they will
become commercially successful products. Forward-looking statements in this
press release should be evaluated together with the many uncertainties that
affect Bristol-Myers Squibb's business, particularly those identified in the
cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form
10-K for the year ended December 31, 2013, in our Quarterly Reports on Form
10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.

About Syngene International

Syngene, a subsidiary of Biocon Ltd, is India's leading contract research
organization offering integrated drug discovery and development services with
capabilities in medicinal chemistry, biology, in vivo pharmacology,
toxicology, custom synthesis, process Research and Development, and
formulation development for small and large molecules. Syngene has an expert
team of over 2,300 scientists and 1 million sq. ft. of built-up laboratories
equipped with state-of-the-art infrastructure to support the Research and
Development programs of global pharma, biotech and nutrition companies. More
information is available at www.syngeneintl.com.

Contact:

Biocon + Syngene
Media:
Seema Ahuja, +91 9972317792
seema.ahuja@biocon.com
or
Rumman Ahmed, +91 98451 04173
rumman.ahmed@biocon.com
or
Investors:
Saurabh Paliwal, +91 9538380801
saurabh.paliwal@biocon.com
or
Sweta Pachlangiya, +91 96865 09372
sweta.pachlangiya@syngeneintl.com
or
Bristol-Myers Squibb
Media:
Frederick J. Egenolf, 609-252-4875
frederick.egenolf@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Ryan Asay, 609-252-5020
ryan.asay@bms.com
 
Press spacebar to pause and continue. Press esc to stop.